Chemopreventive efficacy of oral curcumin: a prodrug hypothesis.


Journal

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484

Informations de publication

Date de publication:
08 2019
Historique:
pubmed: 29 5 2019
medline: 2 6 2020
entrez: 29 5 2019
Statut: ppublish

Résumé

Oral consumption of curcumin, a natural polyphenol, is associated with reduced incidence of cancer. Yet, a significant amount of the orally dosed compound is eliminated in the feces, and a major fraction of the absorbed compound is metabolized to inactive glucuronides, resulting in poor bioavailability (<1%). It is not known how oral curcumin exhibits chemopreventive activity. We propose curcumin glucuronide is an inflammation-responsive natural prodrug that is converted back to curcumin on demand at the site of action. Our studies show elevated levels of β-glucuronidase, an enzyme that hydrolyzes the glycosidic bond of glucuronides to generate the parent compound, in human breast cancer. Oral administration of curcumin in mouse tumor models generated significant tumor levels of the polyphenol. Intravenous administration of the glucuronide resulted in the formation of curcumin in the tumor tissue. Chronic daily oral curcumin dosing led to tumor accumulation of curcumin and inhibition of tumor growth in tumor models with high β-glucuronidase activity. Overall, the study presented here provides preliminary evidence for a novel mechanism of action for orally administered curcumin.-Liu, G., Khanna, V., Kirtane, A., Grill, A., Panyam, J. Chemopreventive efficacy of oral curcumin: a prodrug hypothesis.

Identifiants

pubmed: 31136203
doi: 10.1096/fj.201900166R
pmc: PMC9272759
doi:

Substances chimiques

Glucuronides 0
Prodrugs 0
curcumin glucuronide BE1PK7RL4M
Glucuronidase EC 3.2.1.31
Curcumin IT942ZTH98

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

9453-9465

Subventions

Organisme : NCI NIH HHS
ID : R03 CA141996
Pays : United States

Références

Bioorg Med Chem. 2009 Mar 15;17(6):2623-31
pubmed: 19243951
Drug Deliv Transl Res. 2014 Aug;4(4):344-52
pubmed: 25422796
Cancer. 2005 Sep 15;104(6):1322-31
pubmed: 16092118
Biopharm Drug Dispos. 2006 May;27(4):181-9
pubmed: 16477579
Clin Cancer Res. 2008 Jul 15;14(14):4491-9
pubmed: 18628464
Cancer Res. 1997 Jun 15;57(12):2440-5
pubmed: 9192823
Bioorg Med Chem. 2014 Jan 1;22(1):435-9
pubmed: 24280069
PLoS One. 2017 Nov 30;12(11):e0188873
pubmed: 29190829
Toxicology. 1981-1982;22(4):337-44
pubmed: 7342372
Clin Cancer Res. 2009 Jul 15;15(14):4600-11
pubmed: 19584154
Cancer Res. 2003 Aug 1;63(15):4342-6
pubmed: 12907602
J Am Chem Soc. 2012 Feb 15;134(6):3103-10
pubmed: 22239495
J Cardiovasc Pharmacol Ther. 1997 Oct;2(4):309-320
pubmed: 10684472
J Immunol. 2003 Oct 1;171(7):3863-71
pubmed: 14500688
Food Chem. 2014 May 15;151:126-32
pubmed: 24423511
Naunyn Schmiedebergs Arch Pharmacol. 2000 Aug;362(2):110-5
pubmed: 10961372
Drug Metab Dispos. 2012 Oct;40(10):1993-2001
pubmed: 22807110
Drug Metab Dispos. 1999 Apr;27(4):486-94
pubmed: 10101144
Biomaterials. 2010 Sep;31(25):6597-611
pubmed: 20553984
Lab Invest. 1999 Oct;79(10):1261-9
pubmed: 10532589
Biochem Pharmacol. 2004 Jan 1;67(1):31-9
pubmed: 14667926
FASEB J. 2019 Aug;33(8):9453-9465
pubmed: 31136203
J Biol Chem. 1995 Jul 14;270(28):16483-6
pubmed: 7622446
Cell Physiol Biochem. 2007;19(1-4):137-52
pubmed: 17310108
Mol Cancer Ther. 2009 Apr;8(4):940-6
pubmed: 19372567
J Med Chem. 2017 Mar 9;60(5):1620-1637
pubmed: 28074653
J Pharmacol Exp Ther. 2002 Apr;301(1):223-8
pubmed: 11907177
Pharmacol Ther. 1991;51(3):347-69
pubmed: 1792239
J Pharmacol Exp Ther. 2002 Nov;303(2):649-55
pubmed: 12388647
Mutat Res. 2003 Feb-Mar;523-524:55-62
pubmed: 12628503
J Exp Med. 1998 Aug 3;188(3):589-96
pubmed: 9687535
Methods Mol Med. 2004;90:303-30
pubmed: 14657570
Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1411-7
pubmed: 18559556
J Exp Med. 2001 Nov 5;194(9):1195-205
pubmed: 11696586
Breast Cancer Res. 2007;9(4):211
pubmed: 17705881
Methods Enzymol. 2005;400:263-72
pubmed: 16399354
Toxicology. 1980;16(3):259-65
pubmed: 7423534
Adv Exp Med Biol. 2007;595:227-43
pubmed: 17569214
Nat Rev Cancer. 2004 Jun;4(6):423-36
pubmed: 15170445
Cancer Res. 1998 Mar 15;58(6):1195-201
pubmed: 9515805
Adv Pharm Bull. 2013;3(1):127-30
pubmed: 24312824
Int J Pharm. 2007 Jun 29;338(1-2):27-34
pubmed: 17298869
Oncogene. 2014 Jul 10;33(28):3668-76
pubmed: 23995792
J Natl Cancer Inst. 2001 Feb 21;93(4):266-76
pubmed: 11181773

Auteurs

Garvey Liu (G)

Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.

Vidhi Khanna (V)

Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.

Ameya Kirtane (A)

Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.

Alex Grill (A)

Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.

Jayanth Panyam (J)

Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH